Engagement summary
Client Background
Confluent Medical Technologies is a leading global contract manufacturer of complex medical devices and components for the world's top medical-device OEMs, with expertise in nitinol, catheters, polymer extrusion, and balloon catheters.
Engagement Scope
R&M has served as Confluent's technical-accounting partner since 2019, supporting ASC 480 debt-instrument analyses across multiple capital structure events, ASC 815 embedded-derivative identification and bifurcation, ASC 606 revenue recognition, ASC 842 lease accounting, and ongoing acquisition support.
Services Provided
- ASC 480 debt instrument analysis and classification
- ASC 815 embedded derivative identification and bifurcation
- ASC 606 revenue recognition analysis
- ASC 842 lease accounting and adoption
- ASC 805 acquisition accounting
- 10-K equivalent annual financial reporting (FY 2019 – FY 2020)
Valuation context
Confluent Medical Technologies engaged Rivers & Moorehead for independent valuation support under the standard(s) listed above. The engagement provides valuation analyses, supporting models, and written deliverables intended to assist the company and its external auditors with financial reporting under U.S. GAAP.
Valuation scope
- ASC 718 equity-based compensation valuation – grant-date fair value of stock options, restricted stock, profit interest units, or performance-based awards using Black-Scholes, lattice, or Monte Carlo models as award terms require; supporting documentation for audit.
- ASC 805 purchase price allocation – identification and fair value measurement of acquired identifiable intangible assets (e.g., customer relationships, trade names, developed technology, non-compete agreements), tangible assets, and assumed liabilities, with residual goodwill calculation and opening balance sheet support.